Investing in high-purity guide RNA-Sumitomo Chemical Europe

Content provided by Sumitomo Chemical Europe

Investing in high-purity guide RNA to unlock the power of CRISPR therapies

The world urgently needs new manufacturing capabilities to realise the huge potential of genome editing therapy. Equipped with CRISPR-Cas9 technology, researchers have revealed opportunities to address major unmet medical needs through genome editing...

© GettyImages/CiydemImages

Ncardia secures $60m to expand iPSC platform

Ncardia, a human-induced pluripotent stem cell-based (iPSC) technology company, has secured more than US$60m in capital through a strategic partnership with Kiniciti, a US based investor with a focus on the global cell and gene therapy ecosystem.

Global Industry News

Hot Topics


Follow us


View more


Featured Suppliers

All suppliers